$-0.41
(Market cap
$16 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-17 Mln
-
ROE
-3.1 %
-
ROCE
-- %
-
Industry P/E
33.27
-
EV/EBITDA
11
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-3.5
-
Face value
--
-
Shares outstanding
14,493,111
10 Years Aggregate
CFO
$-188.50 Mln
EBITDA
$-276.51 Mln
Net Profit
$-286.27 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
CEL-SCI Corp (CVM)
| -80.8 | -22.3 | -71.7 | -55.1 | -75.9 | -72.5 | -44.5 |
|
BSE Sensex*
| -9.6 | 1.8 | 2.7 | -5.6 | 6.8 | 7.7 | 11.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
CEL-SCI Corp (CVM)
| -56.2 | -85.1 | 15.7 | -66.9 | -39.1 | 27.4 | 218.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
CEL-SCI Corp (CVM)
|
1.0 | 15.7 | 0.0 | -22.7 | -- | -198.9 | -- | 2.3 |
| 350.5 | 191,704.4 | 37,238.0 | 7,800.0 | 31.7 | 82.9 | 24.7 | 20.9 | |
| 56.2 | 116,663.5 | 48,482.0 | 7,275.0 | 21.6 | 37.7 | 16 | 5.8 | |
| 226.4 | 52,427.0 | 250,549.0 | 1,559.0 | 0.9 | -- | 34.1 | 16.1 | |
| 124.3 | 155,928.8 | 29,734.0 | 9,216.0 | 39.5 | 40.9 | 17.1 | 6.6 | |
| 779.8 | 94,623.4 | 403,430.0 | 4,762.0 | 1.6 | -246.4 | 20.5 | 5.0 | |
| 114.9 | 298,256.0 | 65,593.0 | 8,935.0 | 24.7 | 18.3 | 34 | 6.4 | |
| 151.6 | 293,693.5 | 56,053.0 | 13,533.8 | 30.3 | 32.7 | 22.1 | 7.6 | |
| 26.0 | 149,154.5 | 63,315.0 | 7,491.0 | 16.7 | 8.1 | 20 | 1.6 | |
| 80.0 | 33,358.0 | 9,509.0 | 2,643.0 | 37.3 | 61.2 | 13 | 10.3 |
Shareholding Pattern
View DetailsAbout CEL-SCI Corp (CVM)
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has... completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia. Read more
-
Chief Executive & Financial Officer, Treasurer and Director
Mr. Geert R. Kersten Esq.
-
Chief Scientific Officer
Dr. Eyal Talor Ph.D.
-
Headquarters
Vienna, VA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for CEL-SCI Corp (CVM)
What is the current share price of CEL-SCI Corp (CVM) Today?
The share price of CEL-SCI Corp (CVM) is $1.01 (NYSE) as of 15-Jun-2026 16:07 EDT. CEL-SCI Corp (CVM) has given a return of -75.95% in the last 3 years.
What is the current PB & PE ratio of CEL-SCI Corp (CVM)?
Since, TTM earnings of CEL-SCI Corp (CVM) is negative, P/E ratio is not available.
The P/B ratio of CEL-SCI Corp (CVM) is 2.34 times as on 12-Jun-2026, a 60 discount to its peers’ median range of 5.79 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.90
|
4.62
|
|
2024
|
-0.08
|
0.18
|
|
2023
|
-0.06
|
0.14
|
|
2022
|
-0.12
|
0.14
|
|
2021
|
-0.38
|
0.27
|
What is the 52 Week High and Low of CEL-SCI Corp (CVM)?
The 52-week high and low of CEL-SCI Corp (CVM) are Rs 13.48 and Rs 0.89 as of 16-Jun-2026.
What is the market cap of CEL-SCI Corp (CVM)?
CEL-SCI Corp (CVM) has a market capitalisation of $ 16 Mln as on 12-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in CEL-SCI Corp (CVM)?
Before investing in CEL-SCI Corp (CVM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.